| abstract |
A pharmaceutically acceptable salt of the morpholinobenzamide compound of formula (1) or a solvate of said salt, wherein the compound of formula (1) is like the enantiomer (R), the enantiomer (S) or the racemate with the condition that (R) ûN- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide hydrogen (R) -N- [5methyl-8- ( 4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide hydrogen (2R, 3R) -tartrate, (R) -N- [5-methyl-8- ( 4-methylpiperazin-1-yl) -1,2,3,4, -tetrahydro-2-naphthyl] -4-morpholinobenzamide benzenesulfonate, (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide hydrogen 1,2-ethanedisulfonate, (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1 , 2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide hydrogen maleate. (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide hydrogen sulfate, (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2naphthyl] -4-morpholinobenzamide D-gluconate, (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide hydrogen succinate, (R) -N- [5-methyl-8- (4-methylpiperazin-1 -il) -1,2,3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide methanesulfonate, (R) -N- [5-methyl-8 (4-methylpiperazin-1-yl) -1,2, 3,4-tetrahydro-2-naphthyl] -4-morpholinobenzamide hydrogen (S) -maleate, (R) -N- [5-methyl-8- (4-methylpiperazin-i-yl) -1,2,3, 4-tetrahydro-2-naphthyl] -4-morpholinobenzamide dihydrogen citrate and (R) -N- [5-methyl-8- (4-methylpiperazin-1-yl) -1,2,3,4-tetrahydro-2- naphthyl] -4-morpholinobenzamide hydrochloride is excluded, a process for its preparation, pharmaceutical formulations containing said therapeutically active compounds, and the use of said active compounds for the manufacture of a medicament. They are compounds for therapeutic use, especially compounds that have a selective effect on a subset of 5-hydroxytryptamine receptors, designated the h5-HTiB receptor (previously referred to as the 5-HT receptor (1Dbeta) in mammals, including man, whose compounds are formulated with ease in pharmaceutical combinations They are compounds with a therapeutic effect after oral administration. |